Basics Protalix BioTherapeutics, Inc. Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx. IPO Date: June 1, 1998 Sector: Healthcare Industry: Biotech Market Cap: $124.19M Activated in VL: True Average Daily Range Avg Daily Range: $0.16 | 2.83% Avg Daily Range (30 D): $0.08 | 3.48% Avg Daily Range (90 D): $0.07 | 3.06% Institutional Daily Volume Avg Daily Volume: .44M Avg Daily Volume (30 D): 1.12M Avg Daily Volume (90 D): .82M Trade Size Avg Trade Size (Sh.): 355 Avg Trade Size (Sh.) (30 D): 218 Avg Trade Size (Sh.) (90 D): 204 Institutional Trades Total Inst.Trades: 280 Avg Inst. Trade: $1.47M Avg Inst. Trade (30 D): $7.01M Avg Inst. Trade (90 D): $7.01M Avg Inst. Trade Volume: .07M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $3.88M Avg Closing Trade (30 D): $7.01M Avg Closing Trade (90 D): $7.01M Avg Closing Volume: 544.49K         News Mar 26, 2025 @ 7:00 PM [Latest] Global Fabry Disease Treatment Market Siz... Source: Custom Market Insights Jun 12, 2024 @ 3:45 PM Pluxee to acquire Cobee, an innovative Spanish dig... Source: Pluxee N.V Jun 12, 2024 @ 3:45 PM Pluxee signe un accord pour l’acquisition d... Source: Pluxee N.V Jun 12, 2024 @ 3:45 PM Pluxee firma un acuerdo para adquirir Cobee, empre... Source: Pluxee N.V Apr 22, 2024 @ 4:00 PM Declaration of transactions in own shares n 2024/0... Source: Pluxee International Financials   TTM Q1 2025 Q4 2024 Basic EPS $.05 $-.05 $.09 Diluted EPS $.04 $-.05 $.09 Revenue $ 59.76M $ 10.11M $ 18.22M Gross Profit $ 29.87M $ 1.93M $ 14.33M Net Income / Loss $ 3.91M $ -3.62M $ 6.49M Operating Income / Loss $ 4.63M $ -4.15M $ 7.21M Cost of Revenue $ 29.9M $ 8.18M $ 3.89M Net Cash Flow $ -4.19M $ -.29M $ -7.7M PE Ratio 40.00     Splits Dec 20, 2019:   1:10 Jan 03, 2007:   1:10